<i>TERT</i>promoter mutations contribute to<i>IDH</i>mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomasYing Mao, Yin Wang, Yang Wang et al.|Oncotarget|2015Cited by 36
High-grade thalamic gliomas: Microsurgical treatment and prognosis analysisBiwu Wu, Yi Zhang, Chao Tang et al.|Journal of Clinical Neuroscience|2017Cited by 28
Long term follow-up and outcomes in adult patients with thalamic gliomasZhiqi Li, Yi Zhang, Hanfeng Wu et al.|Clinical Neurology and Neurosurgery|2020Cited by 9
CTNI-52. RETROSPECTIVE ANALYSIS OF USING RADIOTHERAPY WITH CONCURRENT TEMOZOLOMIDE AND TUMOR TREATING FIELDS FOR CHINESE PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMAYang Wang, Chao Li, Jingsong Wu et al.|Neuro-Oncology|2021Cited by 1